I
n the United States, fewer than 50% of adults treated for hypertension reach the recommended blood pressure (BP) target of Ͻ140 mm Hg systolic and Ͻ90 mm Hg diastolic. 1 Better results have been reported in two large clinical trials that used protocol-driven combination regimens to achieve BP control: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CON-VINCE) trial. In these studies, BP target was reached in approximately 60% to 70% of patients. 2, 3 Similarly, several hypertension referral clinics have reported achieving BP target in 50% to 65% of patients, with aggressive use of combination antihypertensive regimens. 4 -6 Even in these settings, however, a significant proportion of patients fail to reach BP targets, most commonly because systolic BP remains elevated. This suggests that existing antihypertensive agents, even used in combination, may not have sufficient efficacy to achieve BP control in all patients.
Omapatrilat is an inhibitor of neutral endopeptidase (NEP) (EC 3.4.24.11; neprilysin; enkephalinase; E-24.11) and angiotensin-converting enzyme (ACE) that has been shown to be more efficacious in BP reduction than several widely used antihypertensive agents. Through simultaneous inhibition of ACE and NEP, omapatrilat protects endogenous vasodilator peptides, including adrenomedullin, the natriuretic peptides, and bradykinin, from degradation and blocks the generation of angiotensin II.
In phase III trials, omapatrilat produced additional reductions in systolic BP at trough (24 h postdose) of 5.5 mm Hg and 24-h ambulatory systolic BP of 6.8 to 8.2 mm Hg relative to comparable doses of lisinopril. [7] [8] [9] Omapatrilat also produced additional reductions in 24-h ambulatory systolic BP of 5.9 mm Hg relative to amlodipine 10 mg. These trials, however, used traditional study design for registrational trials in hypertension. Omapatrilat and control were compared head-to-head at a fixed dose achieved by forced titration and no additional antihypertensive agents were permitted. The trials used a select study population treated under tightly controlled conditions. Whether results comparable to those observed with omapatrilat could also be obtained by using existing drugs in broader populations under conditions resembling clinical practice, with elective titration and use of combination therapy if needed, was not definitively answered by these studies.
These trials also suggested that omapatrilat might be associated with a greater frequency and severity of angioedema than ACE inhibitors. Of 4284 hypertensive subjects treated with omapatrilat in controlled trials, four subjects developed angioedema with airway compromise and required mechanical airway protection. In all, 0.9% of subjects developed angioedema of any severity. An additional 1.0% of subjects developed events classified as "head and neck edema," which may have been angioedema. These event rates were higher than those previously reported to the Food and Drug Administration in registrational trials of ACE inhibitors. The number of subjects studied in head-to-head comparisons of omapatrilat and an ACE inhibitor was too small, however, for any definitive assessment of the relative incidence and severity of angioedema.
The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial was performed to characterize better the risk-benefit relationship of omapatrilat. To assess the effect that a more efficacious monotherapy such as omapatrilat may have on BP control in clinical settings, investigators were provided several opportunities to titrate study therapy and to add additional agents as needed to reach BP target. Eligibility criteria were broad, with few exclusion criteria. The OCTAVE trial was also performed to characterize better the incidence and severity of angioedema relative to a representative ACE inhibitor. Because the incidence of angioedema (including life-threatening angioedema) in previous trials appeared to be substantially lower in patients who had received a 10-mg starting dose than in those who had received higher doses, omapatrilat therapy was started at 10 mg in OCTAVE. Angioedema was assessed prospectively by an expert panel blinded to treatment assignment. The OCTAVE trial was designed to be of adequate size to compare the rate of angioedema with omapatrilat and enalapril, to identify other uncommon but potentially serious side effects, and to assess safety and efficacy in a wide range of demographic and clinical subgroups.
Methods

Study Design
The OCTAVE trial was conducted at 3298 investigative sites in 12 countries (the United States, Canada, United Kingdom, Spain, Italy, Germany, Belgium, The Netherlands, Poland, Russia, Israel, and Australia) under the supervision of appropriate institutional review boards or ethics committees. The first patient was enrolled August 29, 2000, and subject follow-up was completed July 27, 2001. The study was conducted under the principles of the Declaration of Helsinki and in accordance with local regulations. Written informed consent was obtained from all study participants before any study-related procedures. The OCTAVE trial was sponsored by Bristol-Myers Squibb and conducted under the auspices of an independent Steering Committee.
A multicenter, randomized, double-blind, active-controlled design was used for the OCTAVE trial. The 24-week, double-blind treatment period included two phases: 1) a titration phase (weeks 1 to 8), in which omapatrilat and enalapril were titrated as needed to reach target BP; and 2) a maintenance phase (weeks 9 to 24) in which the dose of double-blind study drug was maintained and adjunctive antihypertensive therapy was added as needed to reach target BP.
Subjects who met the inclusion and exclusion criteria for enrollment were scheduled to return for randomization in 1 to 10 days. Blood pressure was reassessed at randomization, and eligible subjects were randomized in equal numbers to omapatrilat or enalapril and were assigned to one of three study groups. Group Omapatrilat was administered starting at 10 mg once daily, force-titrated to 20 mg at week 2, and then electively titrated to 40 mg at week 4 and 80 mg at week 6 as needed to achieve BP control. Enalapril was administered starting at 5 mg once daily, force-titrated to 10 mg at week 2, and then electively titrated to 20 mg at week 4 and 40 mg at week 6 as needed to achieve BP control.
Adjunctive antihypertensive medication could be added to omapatrilat or enalapril at weeks 8, 16, or at interim unscheduled visits during the maintenance phase to achieve BP control.
Subjects
Study subjects were treated or untreated hypertensive subjects at least 18 years of age who met BP criteria for assignment to one of the three study groups as previously described. Exclusion criteria included a contraindication to therapy with ACE inhibitors or angiotensin II receptor antagonists, a history of angioedema, anaphylaxis, druginduced or chronic urticaria, or multiple drug sensitivities, recent hospitalization for myocardial infarction (MI), unstable angina, stroke, transient ischemic attack (TIA), or chronic obstructive pulmonary disease, recent treatment for a malignancy, chronic renal disease secondary to autoimmune disease, or end-stage renal disease of any etiology. Hypertensive subjects treated with ACE inhibitors whose BP would place them in study group 3 were also excluded.
Endpoints and Objectives
The primary endpoints were reduction in systolic BP at week 8 (the end of the titration phase) and the need for new adjunctive antihypertensive therapy by week 24 (the end of the maintenance phase). Secondary efficacy endpoints included reduction in diastolic BP at week 8, reduction in systolic and diastolic BP at week 24, and BP control (SBP Ͻ140 mm Hg and DBP Ͻ90 mm Hg) at weeks 8 and 24. Other key efficacy objectives included characterization of reduction in BP and BP control in subgroups defined by demographics, severity of hypertension, and comorbid conditions (e.g., diabetes). Key safety objectives included summarizing the incidence of severe adverse events and discontinuations because of adverse events, and comparing the incidence and evaluating the severity of angioedema. A summary of the incidence of a cardiovascular composite endpoint, comprised of death or hospitalization for MI, angina, stroke or TIA, or renal failure was also planned.
Blood pressure was measured in the clinic at trough (approximately 24 h postdose) in the seated position using a mercury sphygmomanometer or approved automated device. All potential angioedema events, including any swelling of the head or neck, were reported as potential study endpoints. Detailed follow-up information was obtained on these events using a structured questionnaire. All data were then reviewed in blinded fashion by the Event Adjudication Committee (a panel of experts in angioedema) to determine whether angioedema had occurred. The committee also classified the severity of angioedema according to an ad hoc scale that used measures of treatment intensity as proxies for severity.
Statistical Methods
The first primary objective (comparison of the change in SBP from baseline to week 8 within each study group) was evaluated using a two-sample t test. The degrees of freedom were equal to the number of subjects with available data in both treatment groups minus 2. The second primary objective (comparison of the proportion of subjects adding new adjunctive antihypertensive medications by week 24 within each study group) was evaluated using a Pearson 2 test, at one degree of freedom. For the two primary objectives, a two-sided significance level of .0083 was used, with Bonferroni's correction for six comparisons (three study groups and the two primary efficacy variables). All other efficacy comparisons were evaluated at a nominal significance level of .05.
The two-sided 95% confidence interval for the relative risk of angioedema was calculated using Fieller's theorem. The severity of angioedema was assessed by treatment group using two methods: a proportional odds model and a weighted regression model. All analyses of angioedema were based on cases confirmed by adjudication. No statistical comparisons were carried out on other safety data, nor on the composite cardiovascular endpoint.
An exploratory analysis of the effect of adjunctive antihypertensive therapy on BP control was conducted. The proportion of subjects uncontrolled at week 8 who subsequently received adjunctive therapy was determined for each investigative site. The sites were ranked according to their rate of adjunct use, and grouped into five "adjunct use" categories of equal size. The BP control rate at week 24 was determined by treatment group (omapatrilat or enalapril) within each adjunct use category. Sites with Ͻ10 subjects entering the maintenance phase with uncontrolled BP were excluded from this analysis.
Randomization was blocked by site. The randomization sequence was generated centrally and treatments were allocated by telephone call to the randomization center. Investigative sites, subjects, and the administrative center were blinded to treatment assignments.
The OCTAVE trial was designed to have sufficient power to test the two primary efficacy objectives (comparison of change in systolic BP at week 8 and use of new adjunctive antihypertensive medication by week 24) and an important secondary objective (comparison of the incidence of angioedema by week 8). The sample size of 25,000 randomized subjects was expected to provide at least 95% power for detecting a difference of 3 mm Hg between treatment groups within each study group for the first primary efficacy variable, and at least 81% power to detect a 20% relative reduction for omapatrilat versus enalapril within each study group for the second primary efficacy variable. The sample size was also expected to provide 95% power to exclude a twofold increase in the risk of angioedema with omapatrilat relative to enalapril at a one-sided significance level of .05, assuming the rate of angioedema with enalapril is 0.4%.
Results
Disposition
A total of 25,302 subjects were randomized (12,668 to omapatrilat and 12,634 to enalapril). The 24-week, double-blind treatment period was completed by 81.3% of subjects randomized to omapatrilat and 82.0% of subjects randomized to enalapril. The most common reason for discontinuation was adverse events (8.0% for omapatrilat and 7.5% for enalapril).
Baseline Characteristics
Demographics were comparable for subjects randomized to omapatrilat and enalapril within each study group and overall (Table 1) . Baseline mean systolic BP ranged from 150 to 166 mm Hg, and baseline diastolic BP from 91 to 97 mm Hg, depending on study group. Baseline antihypertensive therapy included two or more agents in 36.4% (4087/11,224) of study group 2 subjects and 50.2% (2386/ 4751) of study group 3 subjects.
Subjects' medical histories are summarized in Table 2 . Approximately 13% of the study population had diabetes and substantial numbers had histories of overt cardiovascular disease (angina, MI, stroke or TIA, heart failure, or renal disease).
Management of Antihypertensive Therapy
The dose of study drug was increased in 85.1% of subjects (13,879/16,306) whose BP was uncontrolled (i.e., exceeded treatment target of Ͻ140/Ͻ90 mm Hg) at week 4 and in 79.0% of subjects (10,191/12,904) in whom BP was uncontrolled at week 6. Adjunctive antihypertensive therapy was added in 36.3% of subjects (3632/10,011) whose BP was uncontrolled at week 8 and in 13.4% of subjects (1117/8307) whose BP was uncontrolled at week 16. Overall, antihypertensive treatment was intensified by uptitration of study drug or addition of adjunctive therapy at 61.2% of visits at which BP exceeded treatment target.
Efficacy Results
Titration of study therapy and mean BP changes from baseline at week 8 are presented in Table 3 . Despite more frequent up-titration of study therapy among subjects randomized to enalapril, greater reductions in BP were observed in subjects randomized to omapatrilat within each study group (P Ͻ .001 for all comparisons). Overall, the mean reduction in SBP was 3.6 mm Hg greater with omapatrilat than with enalapril, and the mean reduction in DBP was 2.0 mm Hg greater with omapatrilat.
Use of adjunctive antihypertensive therapy and mean BP changes from baseline at week 24 are presented in Table 4 . Despite significantly greater use of adjunctive antihypertensive therapy in subjects randomized to enalapril, greater reductions in BP at week 24 were observed in subjects randomized to omapatrilat. Overall, 19% of subjects randomized to omapatrilat received new adjunctive therapy compared with 27% of subjects randomized to enalapril. The mean reduction in SBP was 3.1 mm Hg greater with omapatrilat than with enalapril, and the mean reduction in DBP was 1.6 mm Hg greater with omapatrilat (P Ͻ .001 for all comparisons).
Blood pressure control rates at weeks 8 and 24 are displayed in Fig. 1 . In each study group, BP target (Ͻ140 mm Hg systolic and Ͻ90 mm Hg diastolic) was achieved significantly more often in subjects randomized to omapatrilat than in those randomized to enalapril (P Ͻ .001) for all comparisons. Overall, after 24 weeks of doubleblind treatment, target BP was achieved in 58.2% of subjects who received omapatrilat and 49.6% of those who received enalapril.
In subgroups defined by demographics (age [Ͻ65 years, Ն65 years], sex, and ethnicity [white, black, Asian/ Pacific Islander]), severity of hypertension (JNC-VI stage I, II, or III), or type of hypertension or comorbidity (isolated systolic hypertension, diabetes, atherosclerotic disease, renal disease), subjects randomized to omapatrilat experienced greater mean reductions in systolic BP at week 8 than subjects randomized to enalapril (difference Ϫ2.2 mm Hg to Ϫ6.6 mm Hg), were less likely to receive adjunctive antihypertensive therapy (absolute difference Ϫ4.0% to Ϫ11.0%), and had higher BP control rates at week 24 (absolute difference 6.0% to 11.7%). In the small number of subjects with concomitant heart failure, reductions in systolic BP at week 8 and BP control rates at week 24 were also greater with omapatrilat than enalapril (by 1.1 mm Hg and 4.7%, respectively), but use of adjunctive antihypertensive medication was similar. Reductions in BP in black patients were greater with omapatrilat than with enalapril but were smaller with both drugs than in other subgroups. At week 8, SBP in black patients was reduced Ϫ12.0 mm Hg (95% CI Ϫ11.0 to Ϫ13.0) with Chronic stable angina, n (%)
81 (2) 80 (2) 281 (5) 233 (4) 239 (10) 231 (10) 601 (5) 544 (4) Unstable angina, n (%) 10 (0) 11 (0) 22 (0) 22 (0) 23 (1) 19 (1) 55 (0) 52 (0) MI, n (%)
45 (1) 63 (1) 191 (3) 196 (3) 132 (5) 127 (5) 368 (3) 387 (3) Cardiac surgery, n (%)
48 (1) 68 (1) 211 (4) 206 (4) 115 (5) 125 (5) 374 (3) 399 (3) Parental history of MI, n (%)
268 (6) 310 (7) 371 (7) 384 (7) 138 (6) 142 (6) 777 (6) 837 (7) Congestive heart failure, n (%)
9 (0) 14 (0) 74 (1) 70 (1) 36 (1) 38 (2) 120 (1) 122 (1) Stroke/TIA, n (%)
63 (1) 65 (1) 181 (3) 208 (4) 101 (4) 107 (5) 345 (3) 380 (3) Diabetes, n (%)
374 (8) 401 (9) 924 (17) 899 (16) 413 (17) 365 (16) 1711 (14) 1666 (13) Hypercholesterolemia, n (%) 1100 (24) 1149 (25) 1958 (35) 2078 (37) 889 (37) 802 (34) 3949 (31) 4031 (32) Renal disease, n (%)
46 (0) 55 (1) 168 (3) 157 (3) 91 (4) 97 (4) 305 (2) 311* (2) *Includes two subjects whose study group could not be determined. MI ϭ myocardial infarction; TIA ϭ transient ischemic attack; other abbreviations as in Table 1 . Ϫ12.4 (0.1)
Abbreviations as in Table 1 .
omapatrilat versus Ϫ6.8 mm Hg (95% CI Ϫ5.8 to Ϫ7.9) with enalapril.
Effect of Adjunctive Therapy on Efficacy
The BP control rates at week 24 were stratified in quintiles according to the rate of investigator use of adjunctive therapy in uncontrolled subjects. Each quintile included approximately 1500 to 2000 evaluable subjects. Rates of adjunct use in uncontrolled subjects varied widely, from Ͻ15% at sites where adjunct use was least frequent to Ն64% at sites where adjunct use was most frequent. Regardless of the rate of adjunct use, BP control rates at week 24 were higher with omapatrilat than enalapril. At sites where adjunct use was most frequent, 60.0% of subjects randomized to omapatrilat were controlled at week 24 versus 51.6% of enalapril-treated subjects.
Safety
The incidence of adverse events, serious adverse events, adverse events resulting in discontinuation, and deaths was virtually identical for omapatrilat-and enalapril-treated Change from baseline, mean (SE)
FIG. 1.
Blood pressure control rates by study group at weeks 8 and 24. Target blood pressure (BP) was Ͻ140 mm Hg systolic and Ͻ90 mm Hg diastolic. subjects (Table 5 ). Angioedema occurred in 274 omapatrilat-treated subjects (2.17%) and 86 enalapril-treated subjects (0.68%) during the 24-week, double-blind treatment period (relative risk 3.17, 95% CI 2.52 to 4.12). Treatment with omapatrilat was associated with a greater angioedema severity grade (P Ͻ .005 for both tests). Most cases did not require aggressive treatment; 59% of subjects (161/274) and 76% of subjects (65/86) experiencing angioedema with omapatrilat and enalapril, respectively, received either no treatment or were treated with antihistamines only. Two subjects (both treated with omapatrilat) experienced airway compromise, one requiring mechanical airway protection. Both recovered without significant sequelae. In black patients, the rate of angioedema was increased approximately threefold with both omapatrilat and enalapril (5.54% and 1.62%, respectively). The rate of angioedema was also increased in current smokers receiving omapatrilat (3.93%) but not enalapril (0.81%).
The composite cardiovascular endpoint (death or hospitalization for cardiovascular causes) occurred less frequently in subjects treated with omapatrilat than those treated with enalapril. A total of 121 events (96 per 10,000 individuals treated) were reported in 105 omapatrilattreated subjects versus 145 events (116 per 10,000 treated) in 121 enalapril-treated subjects.
Discussion
Development of new drugs requires careful evaluation of their risk and benefit before marketing and broad use. Recently, several new drugs have been withdrawn from the market after approval because of safety problems. In some cases, the number of subjects studied before approval may have been too small to identify clearly the potential risks (e.g., with troglitazone). In other cases, known safety risks that could be managed safely in highly controlled studies were not managed properly in clinical practice (e.g., with mibefradil).
The OCTAVE trial was performed to provide a more rigorous assessment of the benefits and risks of treatment with omapatrilat, a compound that had been shown to be associated with greater efficacy, but also potentially greater risk, than existing antihypertensive agents. The use of a simple protocol, with broad eligibility criteria and few exclusions, and the very large number of investigative sites allowed the study to be completed in Ͻ1 year.
Subjects randomized to enalapril were more likely to be titrated upward on the study drug and to receive additional antihypertensive medication to supplement enalapril.
Despite receiving a less aggressive pattern of antihypertensive therapy, subjects randomized to omapatrilat had, on average, a 3-mm Hg greater reduction in systolic BP by the end of the trial. The incremental reduction in BP was highly consistent across a broad range of patient subtypes, whether omapatrilat was used as initial therapy for hypertension or as a replacement for or in addition to existing therapy in subjects who had failed to reach target BP. Subjects randomized to omapatrilat also experienced BP control rates that were 8% to 10% higher than those of subjects randomized to enalapril. Thus, OCTAVE suggests that use of a more efficacious monotherapy such as omapatrilat can result in greater BP reductions and a greater likelihood of reaching target BP than existing therapies, even in clinical settings where treatment is individualized with combination antihypertensive regimens.
Recent systematic overviews have confirmed the importance of BP reduction in the prevention of cardiovascular events, and have suggested that differences of 3 mm Hg in systolic BP may result in reductions in cardiovascular events of 15% to 20%. Although OCTAVE was not designed to assess definitively the effects of omapatrilat or enalapril on cardiovascular events, the observed reduction in cardiovascular events with omapatrilat was consistent with its antihypertensive effects. Moreover, OCTAVE was large enough to detect rare but serious events that might offset the anticipated benefit of BP reduction, and none were observed. In addition, in the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE), which compared the effects of omapatrilat and enalapril on morbidity and mortality in patients with chronic heart failure, there was no evidence that omapatrilat exerted adverse effects that might detract from its ability as an antihypertensive to reduce the risk of a cardiovascular event. In fact, in the patients with both hypertension and heart failure in that study, omapatrilat reduced morbidity and mortality more than enalapril to an extent similar to that predicted by its greater antihypertensive efficacy (as seen in OCTAVE). Therefore, it is likely that in patients with hypertension but without heart failure, the observed BP reduction in OCTAVE would result in the expected reduction in cardiovascular events. 10 Therefore, it is likely that the observed BP reduction in OCTAVE would result in the expected reduction in cardiovascular events.
The risk of angioedema was approximately three times greater with omapatrilat than with enalapril. Although most angioedema events were clinically insignificant, two resulted in airway compromise (a rate of 1.6 of 10,000 subjects treated with omapatrilat). Life-threatening cardiovascular events (stroke or MI) occur in hypertensive patients at a rate of 100 to 300 per 10,000 patients per year, depending on underlying cardiovascular risk. A 15% to 20% reduction in these events would exceed, by at least an order of magnitude, the number of life-threatening angioedema events caused. Omapatrilat would therefore appear to have a favorable risk-benefit relationship in the treatment of hypertension, particularly in those patients whose BP is difficult to control with existing agents and who have increased risk of cardiovascular events. In black patients and smokers, however, special caution would need to be taken because of the increased risk of angioedema.
Several limitations of OCTAVE should be mentioned. The trial was six months in duration and included six on-treatment visits. With more time or more visits, investigators may have achieved greater BP reduction with enalapril than was observed. Although the importance of reaching target was emphasized in the protocol, investigator training, newsletters, and periodic reminders, antihypertensive therapy was intensified by up-titration of study drug or addition of other antihypertensive drugs at only 62% of visits at which BP was uncontrolled. Had investigators intensified therapy more frequently, they might have achieved better results with omapatrilat or enalapril. Physicians in OCTAVE, however, intensified antihypertensive therapy at a substantially higher rate than do physicians in practice. In a recent study of a health plan population, antihypertensive therapy was intensified at only 38% of visits at which BP was above target. 11 In another study in a Veterans Affairs population, antihypertensive therapy was intensified at only 21% of visits at which systolic BP was markedly elevated (Ͼ160 mm Hg) with diastolic BP Ͻ95 mm Hg. 12 Moreover, even at OC-TAVE sites where investigators intensified antihypertensive therapy most often, BP target was reached more often with omapatrilat than with enalapril.
The burden of disease associated with inadequate treatment of hypertension is substantial. Coronary heart disease and stroke are the first and third leading causes of death in the United States, accounting for 459,841 and 158,448 deaths, respectively, in 1998. Approximately 35% of atherosclerotic cardiovascular events may be attributable to hypertension. 13 The cost of cardiovascular disease and stroke in 2001 was estimated at $298.2 billion.
14 The improvement in BP observed with omapatrilat in OC-TAVE, above and beyond what was achieved by conventional therapies, may therefore have significant implications for both individual and public health.
